AGP Picks
View all

Life Seal reports early Cygnum data at VEITHsymposium

4 hours ago
Life Seal reports early Cygnum data at VEITHsymposium
By AI, Created 15:15 UTC, Nov 18, 2026, AGP -

Life Seal Vascular presented first-in-human results for its Cygnum aneurysm sac management device at VEITHsymposium 2026 in New York. The early study showed no device-related major adverse events or site-reported endoleaks and a mean 2.9 mm reduction in aneurysm sac diameter at six months.

Why it matters: - Type II endoleaks are a major complication after endovascular aneurysm repair, or EVAR. - Persistent endoleaks can lead to repeat procedures and long-term imaging follow-up. - Life Seal Vascular is testing whether Cygnum can manage the aneurysm sac during the original EVAR procedure instead of waiting to treat leaks later.

What happened: - Life Seal Vascular reported 30-day safety and six-month efficacy results from the first-in-human use of Cygnum at VEITHsymposium 2026 in New York. - The data came from the ASCEND study and were presented by Associate Professor Andrew Holden, MBChB, of Auckland City Hospital and Sean P. Lyden, MD, of the Cleveland Clinic. - The study treated eight patients at sites in New Zealand and Japan. - Patients were selected because their anatomy put them at high risk of Type II endoleak.

The details: - Cygnum is a sac-lining implant placed inside the aneurysm sac, outside the endograft, during a standard EVAR procedure. - The device is designed to cover the lumbar and inferior mesenteric arteries that feed Type II endoleaks. - No device-related major adverse events were reported in any patient. - No site-reported endoleaks of any type were seen at 30 days or six months. - No endoleak-related reinterventions were reported. - All patients with six-month imaging showed aneurysm sac diameter reduction. - The mean sac reduction was 2.9 mm, with a range of 1 mm to 5 mm. - No patient showed sac expansion. - Technical success was 100%. - Mean Cygnum deployment time was 5.6 minutes per device. - The device was used with both Gore and Medtronic endografts.

Between the lines: - The early data suggest Cygnum can be deployed within a standard EVAR workflow without obvious added procedural complexity. - The lack of endoleaks through six months is encouraging, but the study is very small and early. - The strongest signal so far is sac stability and shrinkage in every imaged patient, which supports the device’s preventive approach. - Life Seal Vascular is positioning Cygnum as an adjunct to EVAR, not a rescue treatment after complications develop.

What's next: - ASCEND continues enrollment toward as many as 15 patients. - Follow-up is planned through five years. - Life Seal Vascular said the early results support expansion of ASCEND and preparation for a U.S. pivotal study. - Cygnum remains investigational and is not approved for commercial use. - ASCEND is a single-arm, single-center first-in-human study with a primary endpoint of 30-day safety. - Secondary assessments include procedural success, endoleak outcomes and change in aneurysm sac diameter. - The study includes independent imaging core lab review and events adjudication. - The trial is listed as ClinicalTrials.gov ID NCT07020611.

The bottom line: - Life Seal Vascular’s first-in-human Cygnum results are an early sign that sac management during EVAR may help prevent Type II endoleaks and reduce aneurysm sac size.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Wellington Times Gazette

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Wellington Times Gazette

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.